Please login to the form below

Not currently logged in
Email:
Password:

The Accenture Award for Company of the Year (>£150m)

Finalist

GlaxoSmithKline


Summary of work

GlaxoSmithKline is the second largest pharmaceutical company by value in the UK and employs more than 14,700 people across the regions. It has offices in over 100 countries and major research centres in the UK, US, Belgium and China.

GSK is the largest private sector funder of R&D in the UK. In 2010, the company spent £1.8bn, a sum that equates to over 40 per cent of its global R&D spend.

In the same year, GSK launched Arzerra for refractory chronic lymphocytic leukaemia (CLL), Revolade for the treatment of chronic immune thrombocytopenic purpura (ITP), Combodart for treatment of benign prostatic hyperplasia (enlarged prostate), Prolia for the treatment of post-menopausal osteoporosis and Votrient for the treatment of renal cell carcinoma. In addition, the company delivered 1.4 billion vaccine doses to 179 countries.

GSK is one of the few pharmaceutical companies researching both medicines and vaccines for the World Health Organisation’s three priority diseases – HIV/AIDS, tuberculosis and malaria, and is proud to have developed some of the leading global medicines in these fields.

In the UK, as a leading supplier of medicines and vaccines to the NHS, GSK provides treatments for conditions such as asthma, COPD, depression, diabetes, epilepsy, HIV/AIDS, cancer and infections (antibiotics), as well as a wide range of vaccines to prevent childhood, adolescent, adult and travel related illnesses, including influenza.

Judges comments

"GSK approaches everything that it does with a 'win, win, win' attitude – for patients, for the NHS and the company. Its commitment to CSR is very impressive, especially in the Third World. GSK genuinely wants to improve worldwide health.”